Original Article
Endoscopy
Impact of Artificial Intelligence on Colonoscopy Surveillance After Polyp Removal: A Pooled Analysis of Randomized Trials

https://doi.org/10.1016/j.cgh.2022.08.022Get rights and content
Under a Creative Commons license
open access

Background and Aims

Artificial intelligence (AI) tools aimed at improving polyp detection have been shown to increase the adenoma detection rate during colonoscopy. However, it is unknown how increased polyp detection rates by AI affect the burden of patient surveillance after polyp removal.

Methods

We conducted a pooled analysis of 9 randomized controlled trials (5 in China, 2 in Italy, 1 in Japan, and 1 in the United States) comparing colonoscopy with or without AI detection aids. The primary outcome was the proportion of patients recommended to undergo intensive surveillance (ie, 3-year interval). We analyzed intervals for AI and non-AI colonoscopies for the U.S. and European recommendations separately. We estimated proportions by calculating relative risks using the Mantel-Haenszel method.

Results

A total of 5796 patients (51% male, mean 53 years of age) were included; 2894 underwent AI-assisted colonoscopy and 2902 non-AI colonoscopy. When following U.S. guidelines, the proportion of patients recommended intensive surveillance increased from 8.4% (95% CI, 7.4%–9.5%) in the non-AI group to 11.3% (95% CI, 10.2%–12.6%) in the AI group (absolute difference, 2.9% [95% CI, 1.4%–4.4%]; risk ratio, 1.35 [95% CI, 1.16–1.57]). When following European guidelines, it increased from 6.1% (95% CI, 5.3%–7.0%) to 7.4% (95% CI, 6.5%–8.4%) (absolute difference, 1.3% [95% CI, 0.01%–2.6%]; risk ratio, 1.22 [95% CI, 1.01–1.47]).

Conclusions

The use of AI during colonoscopy increased the proportion of patients requiring intensive colonoscopy surveillance by approximately 35% in the United States and 20% in Europe (absolute increases of 2.9% and 1.3%, respectively). While this may contribute to improved cancer prevention, it significantly adds patient burden and healthcare costs.

Keywords

Computer-Aided Diagnosis
Surveillance Interval
Machine Learning

Abbreviations used in this paper

ADR
adenoma detection rate
AI
artificial intelligence
CRC
colorectal cancer
ESGE
European Society of Gastrointestinal Endoscopy
SSL
sessile serrated lesions
USMSTF
U.S. Multi-Society Task Force on Colorectal Cancer

Cited by (0)

Conflicts of Interest These authors disclose the following: Yuichi Mori and Masashi Misawa have served as consultants and received equipment on loan from Olympus; and have ownership interest in Cybernet System. Alessandro Repici has served as a consultant for Fujifilm and Cosmo Pharmaceuticals; received research grant support from Fujifilm and Boston Scientific; has served on the advisory board for Medtronic; and has received speaker fees from Medtronic and Boston Scientific. Michael Bretthauer has served as a consultant for Cybernet System. Seth A. Gross has served as a consultant for Olympus, Cook, Cook, Pentax, Ambu, and Iterative Scopes; and served on the advisory board for Docbot. Douglas K. Rex has an ownership interest in Satisfai Health; and has served as a consultant for Olympus. Prateek Sharma has served as a consultant for Medtronic, Olympus, Boston Scientific, Fujifilm, Salix Pharmaceuticals, and Lumendi; and received research grant support from Ironwood, Erbe, Docbot, Cosmo Pharmaceuticals, and CDx Labs. Tyler M. Berzin has served as a consultant for Medtronic, Boston Scientific, Wision AI, and Magnetiq AI; and served on the advisory board for Docbot AI. Cesare Hassan has served as a consultant for Medtronic, Fujifilm, and Pentax; and received equipment on loan from Medtronic and Fujifilm. All remaining authors disclose no conflicts.

Funding Yuichi Mori was supported by the European Commission (Horizon2020 MSCA-IF No. 101026196) and the Japan Society for the Promotion of Science (No. 19KK0421). Shunsuke Kamba was supported by the Japan Agency for Medical Research and Development (18ck0106272h0002).

Authors share co-first authorship.